Navigation Links
CNIO and Merck sign license agreement for the development of new cancer drugs
Date:12/18/2013

The Spanish National Cancer Research Centre (CNIO) and the German chemical and pharmaceutical company Merck today signed an agreement in Madrid to collaborate in the area of cancer drug development. This global option and license agreement will encourage the development and commercialisation of new compounds in the field of oncology.

With this agreement, the CNIO has granted to Merck exclusive rights to develop and commercialise their new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase. In exchange, Merck will make an initial payment along with other potential income of up to nearly 19 million euros, as well as royalties on net sales.

This agreement is the result of Merck Serono, the biopharmaceutical division of Merck, evaluating a group of ATR inhibitors developed entirely by the CNIO, via its Experimental Therapies Programme and the Genomic Instability Group, led by Joaqun Pastor and scar Fernndez-Capetillo, respectively.

Carmen Vela, Spanish Secretary of State for R&D, who signed the agreement as President of the CNIO Board of Trustees, expressed her satisfaction "at this public-private partnership between a world class research centre and one of the biggest pharmaceutical companies in the world." The Secretary of State underlined the need for "increasing involvement of the private sector in all aspects of Spanish R&D including execution and funding."

"Part of Merck's commitment to oncology includes the focus on strategic agreements that allow us to foster a constant flow of innovations," said Andree Blaukat, Head of Translational Innovation Platform Oncology for Merck Serono. "We are convinced that working with like-minded organizations, like the CNIO, will further strengthen our efforts towards finding the next generation of breakthrough therapies."

"As a research organisation, the CNIO is committed to fostering and promoting innovation. Among other initiatives, the CNIO's Experimental Therapeutics Program carries out early drug discovery projects. The CNIO is delighted to be working with Merck to hopefully translate this research into potential new treatment options for patients with cancer," said Mara Blasco, Director of the CNIO. "It is through collaborations with industry oncology leaders that we can bring CNIO discoveries, such as those made by the group led by Oscar Fernndez-Capetillo, to patients, and contribute new improved products to the battle against cancer."

The agreement encompasses the licensing of two series of ATR inhibitors, as well as a screening platform to validate the compounds, which have currently reached an advanced preclinical stage.

ATR kinase has an important role in the response to DNA damage and in facilitating cell survival. Due to the fact that tumour cells accumulate more DNA damage than healthy cells, blocking ATR kinase activity with selective inhibitors appears to be a strategy worth investigating further for specific tumour types.


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Related medicine news :

1. Fosamax Lawsuits Update: Rottenstein Law Group LLP Comments on Reported $28 Million Merck ‘Jaw Death’ Settlement
2. Merck for Mothers Supports UNICEF’s Efforts to Help Save Lives in South Africa
3. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
4. Merck scientist Daria Hazuda presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
5. Merck and Regenstrief Institute establish evidence-based care collaboration
6. Miami Plastic Surgeon Jon Harrell Advises Patients to Always Use a Licensed Surgeon
7. For The First Time Ever Colorado Issues Recreational Marijuana Sales License
8. Fem Med Formulas Announces an Exclusive License Agreement with NewBridge Pharmaceuticals
9. Wayne State part of team for license on new ways to manage cancer with green tea extracts
10. SeniorQuote Insurance Services Licensed to Support Kansas
11. 265 NY Ambulance and ALS First Responders to Face Stricter License Requirements Regarding Narcotics – MedixSafe Provides Necessary & Reliable Narcotics Security Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... It may be hard to imagine ... to people in the third world. Diseases that many developed countries consider rare or ... don't have access to vaccines. , On an upcoming segment of "Success Files", actor ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... Engineering (ISPE) will host its 2017 Process Validation and Process Validation ... offer comprehensive solutions to process validation lifecycle challenges faced by process validation ...
(Date:7/26/2017)... 92660 (PRWEB) , ... July 26, 2017 ... ... Prevention for on-premises, off and in the cloud ; today announced the availability ... scientific algorithms within a simple to use control console for Data Discovery, Classification, ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with ... to schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing ... directory will bring more Six Month Smiles patients to their providers.” , Each month, ...
(Date:7/26/2017)... ... 2017 , ... IDC-Eating Disorder Care is excited to announce Dr. ... Royal Oak, Michigan. IDC, formerly known as Inner Door Center, was acquired ... standards in the field of eating disorder treatment in the state of Michigan. ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... N.J. , July 11, 2017  Bayer has awarded ... eight countries as part of its prestigious Bayer Hemophilia Awards ... Hospital of Philadelphia and Uniformed Services ... are among the winners. Grant recipients were announced last ... and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, ... urinalysis diagnostic testing equipment as well as middleware ... a way to make quality assurance easier and ... "Sysmex is well known for the innovation that ... Quality Monitor elevates quality assurance processes to a ...
Breaking Medicine Technology: